Lv3
392 积分 2024-07-16 加入
A pilot phase 2a, randomized, double-blind, placebo-controlled study to explore the antiviral activity, clinical outcomes, safety, and tolerability of rilematovir at two dose levels in non-hospitalized adults with respiratory syncytial virus infection
24天前
已完结
Population Pharmacokinetic Modeling of JNJ-53718678, a Novel Fusion Inhibitor for the Treatment of Respiratory Syncytial Virus: Results from a Phase I, Double-Blind, Randomized, Placebo-Controlled First-in-Human Study in Healthy Adult Subjects
24天前
已完结
Advances in respiratory virus therapeutics – A meeting report from the 6th isirv Antiviral Group conference
25天前
已完结
Respiratory syncytial virus in adults with comorbidities: an update on epidemiology, vaccines, and treatments
25天前
已完结
Current state and challenges in respiratory syncytial virus drug discovery and development
28天前
已完结
Recent advances of the respiratory syncytial virus inhibitors
28天前
已完结
Defining RSV epidemic season in southwest China and assessing the relationship between birth month and RSV infection: A 10‐year retrospective study from June 2009 to May 2019
1个月前
已完结
Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis
1个月前
已完结
Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir
1个月前
已完结
Salt Selection and Optimisation Procedures for Pharmaceutical New Chemical Entities
2个月前
已完结
皖公网安备34019202002308
